Acylated glucagon analogues
US9156901B2 · kind B2 · utility
24Cited by
5References
14Claims
0Family size
Inventors
Key dates
| Filing date | Jun 24, 2010 |
| Grant date | Oct 13, 2015 |
| Priority date | — |
| Expiry date | Jun 12, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K14/605
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes and associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.